Cardio-Kidney Effects of Dapagliflozin in Patients at Elevated Cardiovascular Risk with or Without Type 2 Diabetes
Vikas S. Sridhar(University Health Network), David Z.I. Cherney(University Health Network), Massimo Nardone(University Health Network), Dylan Burger(University of Ottawa), Leif E. Lovblom(University of Toronto), Yangqing Deng(University Health Network), Yuliya Lytvyn(University Health Network), Luxcia Kugathasan(University of Toronto), Julie A. Lovshin(Sunnybrook Health Science Centre), Jasper Stevens(University Medical Center Groningen), Hongyan Liu(University of Toronto), John S. Floras(Sinai Health System), Bruce A. Perkins(Sinai Health System), Hiddo Jan L. Heerspink, Josephine Tse(University Health Network)
Cited by 0
Related Papers
Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines
|Journal of Extracellular Vesicles|2018|11.4k
Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials
|The Lancet|2022|1k
Sodium Glucose Cotransporter-2 Inhibition in Heart Failure
|Circulation|2017|470
Urinary extracellular vesicles: A position paper by the Urine Task Force of the International Society for Extracellular Vesicles
|Journal of Extracellular Vesicles|2021|410
Refractory hypertension and sleep apnoea: effect of CPAP on blood pressure and baroreflex
|European Respiratory Journal|2003|300